| 主題 |
日期
(日/月/年) |
|
這連結會以新視窗打開Vigilance against B virus infection and addition of the infection to the list of “Other communicable diseases of topical public health concern” (只備英文版)
|
5-4-2024 |
|
這連結會以新視窗打開Ezetrol (ezetimibe) and the risks of drug-induced liver injury and severe cutaneous adverse reactions (Letter to Healthcare Professionals) (只備英文版)
|
28-3-2024 |
|
這連結會以新視窗打開Amiodarone: Assessing the potential risk of primary graft dysfunction following heart transplantation (Letter to Healthcare Professionals) (只備英文版)
|
28-3-2024 |
|
這連結會以新視窗打開Ibrance (palbociclib): Assessing the potential risk of venous thromboembolism (Letter to Healthcare Professionals) (只備英文版)
|
28-3-2024 |
|
這連結會以新視窗打開Updated warnings of faricimab (Vabysmo): retinal vasculitis risk (Letter to Healthcare Professionals) (只備英文版)
|
21-3-2024 |
|
這連結會以新視窗打開Colistin (colistimethate sodium): Assessing the potential risk of pseudo-Bartter syndrome (Letter to Healthcare Professionals)(只備英文版)
|
1-3-2024 |
|
這連結會以新視窗打開Vigilance against upsurge of measles(只備英文版)
|
29-2-2024 |
|
這連結會以新視窗打開Vigilance against ceftriaxone reduced susceptible Neisseria gonorrhoeae infection
|
30-1-2024 |
|
這連結會以新視窗打開Safety-related information for the product Mifegyne (Letter to Healthcare Professionals) (只備英文版)
|
25-1-2024 |
|
這連結會以新視窗打開含mifepristone成分藥品安全資訊 (Letter to Healthcare Professionals)
|
24-1-2024 |
|
這連結會以新視窗打開BCMA- and CD19-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapies: risk of T cell malignancies (Letter to Healthcare Professionals) (只備英文版)
|
24-1-2024 |
|
這連結會以新視窗打開Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate in the United Kingdom (Letter to Healthcare Professionals) (只備英文版)
|
23-1-2024 |
|
這連結會以新視窗打開Arrival of the 2023/24 Winter Influenza Season in Hong Kong
|
11-1-2024 |